PLX

PLX R&D Expenses

$19.88MTTM · USD

Period ending:

PLX FY R&D ExpensesUSD
PLX FY R&D Expenses1996-12-31: $0.001997-12-31: $0.001998-12-31: $0.001999-12-31: $0.002000-12-31: $0.002001-12-31: $0.002002-12-31: $0.002003-12-31: $0.002004-12-31: $0.002005-12-31: $3.52M2006-12-31: $5.25M2007-12-31: $12.86M2008-12-31: $17.40M2009-12-31: $21.64M2010-12-31: $29.95M2011-12-31: $31.04M2012-12-31: $28.69M2013-12-31: $29.23M2014-12-31: $27.35M2015-12-31: $20.03M2016-12-31: $30.41M2017-12-31: $28.83M2018-12-31: $33.33M2019-12-31: $44.62M2020-12-31: $38.17M2021-12-31: $29.73M2022-12-31: $29.35M2023-12-31: $17.09M2024-12-31: $12.97M2025-12-31: $19.05M$44.62M$0.00
1996-12-312025-12-31

Source: Financial Modeling Prep (FMP). Annual fiscal periods; reported in USD. Dates are period ends; a fiscal year may differ from a calendar year.

PLX r&d expenses history

Research and development spending. The available annual fiscal periods series contains 30 observations from Dec 31, 1996 to Dec 31, 2025.

Protalix Biotherapeutics Inc R&D Expenses — Annual fiscal periods (USD)
Period endingR&D Expenses (USD)
19,054,000
12,970,000
17,093,000
29,349,000
29,734,000
38,167,000
44,616,000
33,330,000
28,834,000
30,412,000
20,025,000
27,352,000
29,225,000
28,689,000
31,043,000
29,951,000
21,638,000
17,401,000
12,861,000
5,246,000
3,524,000
0
0
0
0
0
0
0
0
0

Compare r&d expenses

All PLX financial metrics · PLX stock overview · How to interpret financial metrics

Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.